Yakir Reshef

Yakir Reshef

Auto-generated profile, based on publicly available information

Yakir Reshef

Center for Data Sciences, Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HFHilary K. Finucane
Hilary K. Finucane
YRYakir A. Reshef
Yakir A. Reshef
VAVerneri Anttila
Verneri Anttila
KSKamil Slowikowski
Kamil Slowikowski
AGAlexander Gusev
Alexander Gusev
APAlkes L. Price
Alkes L. Price

16 November 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OWOmer Weissbrod
Omer Weissbrod
FHFarhad Hormozdiari
Farhad Hormozdiari
CBChristian Benner
Christian Benner
RCRan Cui
Ran Cui
JUJacob Ulirsch
Jacob Ulirsch
APAlkes L. Price
Alkes L. Price

3 September 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YRYakir A. Reshef
Yakir A. Reshef
HFHilary K. Finucane
Hilary K. Finucane
DKDavid R. Kelley
David R. Kelley
AGAlexander Gusev
Alexander Gusev
DKDylan Kotliar
Dylan Kotliar
APAlkes L Price
Alkes L Price

19 August 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DRDavid N. Reshef
David N. Reshef
YRYakir A. Reshef
Yakir A. Reshef
MMMichael Mitzenmacher
Michael Mitzenmacher
PSPardis C. Sabeti
Pardis C. Sabeti

8 May 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
BGBryce van de Geijn
Bryce van de Geijn
HFHilary Finucane
Hilary Finucane
SGSteven Gazal
Steven Gazal
FHFarhad Hormozdiari
Farhad Hormozdiari
TATiffany Amariuta
Tiffany Amariuta
APAlkes L Price
Alkes L Price
Regulatory variation plays a major role in complex disease and that cell type-specific binding of transcription factors (TF) is critical to gene regulation. However, assessing the contribution of genetic variation in TF-binding sites to disease heritability is challenging, as binding is often cell type-specific and annotations from directly measured TF binding are not currently available for most cell type-TF pairs. We investigate approaches to annotate TF binding, including directly measured chromatin data and sequence-based predictions. We find that TF-binding annotations constructed by intersecting sequence-based TF-binding predictions with cell type-specific chromatin data explain a large fraction of heritability across a broad set of diseases and corresponding cell types; this strategy of constructing annotations addresses both the limitation that identical sequences may be bound or unbound depending on surrounding chromatin context and the limitation that sequence-based predictions are generally not cell type-specific. We partitioned the heritability of 49 diseases and complex traits using stratified linkage disequilibrium (LD) score regression with the baseline-LD model (which is not cell type-specific) plus the new annotations. We determined that 100 bp windows around MotifMap sequenced-based TF-binding predictions intersected with a union of six cell type-specific chromatin marks (imputed using ChromImpute) performed best, with an 58% increase in heritability enrichment compared to the chromatin marks alone (11.6× vs. 7.3×, P = 9 × 10−14 for difference) and a 20% increase in cell type-specific signal conditional on annotations from the baseline-LD model (P = 8 × 10−11 for difference). Our results show that TF-binding annotations explain substantial disease heritability and can help refine genome-wide association signals.

17 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
OWOmer Weissbrod
Omer Weissbrod
FHFarhad Hormozdiari
Farhad Hormozdiari
CBChristian Benner
Christian Benner
RCRan Cui
Ran Cui
JUJacob Ulirsch
Jacob Ulirsch
APAlkes L. Price
Alkes L. Price
Fine-mapping aims to identify causal variants impacting complex traits. Several recent methods improve fine-mapping accuracy by prioritizing variants in enriched functional annotations. However, these methods can only use information at genome-wide significant loci (or a small number of functional annotations), severely limiting the benefit of functional data. We propose PolyFun, a computationally scalable framework to improve fine-mapping accuracy using genome-wide functional data for a broad set of coding, conserved, regulatory and LD-related annotations. PolyFun prioritizes variants in enriched functional annotations by specifying prior causal probabilities for fine-mapping methods such as SuSiE or FINEMAP, employing special procedures to ensure robustness to model misspecification and winner’s curse. In simulations with in-sample LD, PolyFun + SuSiE and PolyFun + FINEMAP were well-calibrated and identified >20% more variants with posterior causal probability >0.95 than their non-functionally informed counterparts (and >33% more fine-mapped variants than previous functionally-informed fine-mapping methods). In simulations with mismatched reference LD, PolyFun + SuSiE remained well-calibrated when reducing the maximum number of assumed causal SNPs per locus, which reduces absolute power but still produces large relative improvements. In analyses of 49 UK Biobank traits (average N =318K) with in-sample LD, PolyFun + SuSiE identified 3,025 fine-mapped variant-trait pairs with posterior causal probability >0.95, a >32% improvement vs. SuSiE; 223 variants were fine-mapped for multiple genetically uncorrelated traits, indicating pervasive pleiotropy. We used posterior mean per-SNP heritabilities from PolyFun + SuSiE to perform polygenic localization, constructing minimal sets of common SNPs causally explaining 50% of common SNP heritability; these sets ranged in size from 28 (hair color) to 3,400 (height) to 2 million (number of children). In conclusion, PolyFun prioritizes variants for functional follow-up and provides insights into complex trait architectures.